this systematic review and meta-analysis aimed to provide a contemporaneous estimate of the global burden of rheumatic heart disease (RHD) from echocardiographic population-based studies. We searched multiple databases between January 01, 1996 and October 17, 2017. Random-effect meta-analysis was used to pool data. We included 82 studies (1,090,792 participant) reporting data on the prevalence of RHD and 9 studies on the evolution of RHD lesions. The pooled prevalence of RHD was 26.1‰ (95%CI 19.2-33.1) and 11.3‰ (95%CI 7.2-16.2) for studies which used the World Heart federation (WHf) and World Health organization (WHo) criteria, respectively. the prevalence of RHD varied inversely with the level of a country's income, was lower with the WHo criteria compared to the WHF criteria, and was lowest in South East Asia. Definite RHD progressed in 7.5% (95% CI 1.5-17.6) of the cases, while 60.7% (95% CI 42.4-77.5) of cases remained stable over the course of follow-up. The proportion of cases borderline RHD who progressed to definite RHD was 11.3% (95% CI 6.9-16.5). The prevalence of RHD across WHo regions remains high. the highest prevalence of RHD was noted among studies which used the WHF diagnostic criteria. Definite RHD tends to progress or remain stable over time.
Data extraction and management. Two review authors (VNA and UFN) independently extracted relevant data from included studies using a preconceived and standardized abstraction form. Disagreements between these authors were reconciled through discussion and consensus. Two review authors (JJN and JJB) cross-checked the database for errors. Data were extracted from each study on: the surname of the first author, year of publication, area (rural vs urban), country of recruitment of participants, study design, sampling method, male proportion, age distribution, setting (school-based vs community-based), diagnostic approach (auscultation only for screening with second-line echocardiographic confirmation [auscultation > echo], first-line echocardiography with or without auscultation with second line echocardiographic confirmation [echo > echo], and first line echocardiography without confirmation [echo > nothing]), diagnostic criteria (World Health Organization, WHF criteria, and others), the number of participants with clinically silent and manifest RHD, and with borderline and definite RHD. Clinically manifest RHD was defined as the presence of a heart murmur on cardiac auscultation with evidence of RHD on echocardiography (pathological mitral regurgitation or stenosis and/or morphological features of RHD), while absence of heart murmur with echocardiographic evidence of RHD were considered as cases of clinically silent RHD 7 . Where relevant data were not available, we contacted the corresponding author to request the information. Using the country in which the study was conducted in and year of recruitment, we assigned gross domestic product per capita (GDP) in United State dollars 12 , WHO regions 13 , United Nations Statistics Division (UNSD) of countries by continent 14 , situation or not in endemic area 15 , human development index (HDI) 16 , the 2016 level of income 17 , and GINI coefficient 18 . For multinational studies, data were presented according to the country where the study was conducted in.
Data synthesis and analysis. All analyses were performed using 'meta' packages of R (version 3.3.3) (The R foundation for statistical computing, Vienna, Austria). Freeman-Tukey double arcsine transformation was used to pool data by random effect meta-analysis 19 . Following crude overall prevalence, a sensitivity analysis was conducted considering only studies with a low risk of bias. We assessed inter-rater agreement for inclusion and quality assessment using Cohen's kappa (κ) coefficient. All prevalence estimates were reported per 1000 people (‰) with their 95% confidence interval (95%CI) and their 95% predictive interval (95%PI).
We appraised heterogeneity between studies using Cochran's Q statistic, H and the I 2 statistics 20, 21 , which estimate the percentage of total variation across studies due to true between-study difference rather than chance, with I 2 values of 25%, 50% and 75% representing low, medium and substantial heterogeneity, respectively. We explored sources of heterogeneity through subgroup and meta-regression analyses defined by mean/median age, proportion of males, diagnostic approach, diagnostic criteria, study setting, area, WHO regions, UNSD of countries, clinical significance of RHD, level of income, GINI, HDI, GDP, and situation in endemic area. Comparisons between subgroups were performed using the Q-test based on the Analysis of the Variance (ANOVA). Univariable and multivariable meta-analyses were used. To be included in the multivariable analysis, a p value < 0.20 was required in univariable analysis. For categorical variables, the global p value was considered for inclusion in the multivariable model. We applied a manual backward selection procedure to identify factors independently associated with the variation of overall prevalence of RHD. We successively removed variables from the model if p value > 0.10. In the case of non-linear distribution, we log-transformed the covariate before conducting the meta-regression analyses. Publication bias was evaluated with funnel plots supplemented by formal statistical assessment using Egger's test 22 . A p value < 0.10 was considered statistically significant to detect publication bias.
Results
the review process. A total of 7969 records were retrieved via databases searches. After removing duplicates, we screened the titles and abstracts of 5592 records, of which 215 were selected for full-text review. Of these, 81 articles were included in the review, 72 providing data on the prevalence of RHD (in a total of 82 individual studies), 6 reporting data on the evolution of RHD lesions, and 3 on both the prevalence and the evolution of RHD ( Fig. 1 ), all published from 1996 to 2017 . Inter-rater agreements for inclusion based on titles and abstracts, full texts, and for assessment of the methodological quality of finally included studies between review authors were κ = 0.68, 0.98, and 0.87 respectively. characteristics of included studies reporting on the prevalence of RHD. Regarding methodological quality, 51 (62%) had low risk of bias, 30 (37%) had moderate risk of bias, and one (1%) had high risk of bias. The inter-rater agreement for quality assessment was excellent (κ = 0.97). The characteristics of included studies from 35 countries are summarized in the Appendix (Supplementary Tables 6-8 ). Most of studies were school-based (78%, n = 64), conducted both in urban and rural settings, in endemic areas (84.1%, n = 69) of low-middle income countries (41.5%, n = 34). The most represented WHO regions were Africa (26.8%, n = 22), South-East Asia (26.8%, n = 22) and Western Pacific (24.4%, n = 20). On the other hand, the most represented UNSD continent were Asia and Africa. The majority of studies used the WHF (39%, n = 32) and WHO criteria (36.6%, n = 30), and the echo > echo procedure (51.1%, n = 46). Participants were recruited from 1991 to 2015. The mean or median age of participants varied from 8 to 48 years (48 studies); range from 3 to 74 years (74 studies). The proportion of male participants varied from 30% to 65% (58 studies). The sample size in included studies varied from 337 to 229,829 participants. The median GDP, Subgroup analyses. When considering WHF and WHO criteria, the prevalence differed between levels of income but this difference was not found when considering diagnostic procedure. Regardless of diagnostic criteria or procedure, there was no difference between endemic and non-endemic areas, between rural and urban areas, and between community-based and school-based studies. Regardless of diagnostic criteria or procedure, there was difference between UNSD regions and WHO regions (Appendix, Supplementary Table 9 ). factors associated with the prevalence of rheumatic heart disease. In the univariable meta-regression analysis, the RHD prevalence was associated with the year of publication, GDP, GINI coefficient, proportion of males, diagnostic procedure, diagnostic criteria, WHO regions, UNSD of countries, and level of income. In the final multivariable model, the prevalence of RHD was lowest in South-East Asia compared to WHO regions. The RHD significantly decreased with rising level of income; low income countries had higher RHD prevalence. Compared with the WHF diagnostic criteria, the prevalence of RHD estimated with WHO criteria was significantly lower. UNSD of countries by continent was not associated with RHD prevalence. Variables included in the final model explained 57.3% of the 98.4% residual heterogeneity of the RHD prevalence ( Table 2) .
For each meta-analysis, we found some substantial heterogeneity across the included studies overall and within subgroups (Table 1 and Supplementary Table 9 in the Appendix,). There was some evidence of publication bias across the contributing studies (Appendix, Supplementary Table 9 ). For overall RHD prevalence analyses, the publication bias was found for all analyses except for WHF criteria and echo > nothing procedure ( evolution of clinically silent rheumatic heart disease. Supplementary Fig. 8 in the Appendix summarizes studies reporting on the evolution of definite RHD and borderline RHD. The majority of studies were from the Western Pacific and Africa, and published from 2011 to 2017. The ages of a total of 824 participants ranged from ranged from 5-18 years. The proportion of participants on penicillin prophylaxis ranged from 18.8-100% with only three studies reporting on the adherence rate to secondary prophylaxis. The median duration of follow-up ranged from 3.7-90 months. Table 3 depicts the evolution of definite and borderline RHD, and nonspecific valvular abnormalities. Definite RHD progressed in 7.5% (95% CI 1.5-17.6) of the cases, while 60.7% (95% CI 42.4-77.5) of cases remained stable over the course of follow-up. On the other hand, the progression rate for borderline RHD was 11.3% (95% CI 6.9-16.5). Moderate and substantial heterogeneity was noted across included studies overall, with no evidence of publication bias. Stable or progressed lesions were mostly determined by increasing age, presence of a functional aortic valve abnormality, higher durations from diagnosis, receipt of secondary prophylaxis, and presence of a pathological mitral regurgitation murmur ( Fig. 3 ).
Discussion
This systematic review and meta-analysis provides a critical summary of the global prevalence of RHD based on data pooled from 82 observational community-and school-based studies involving 1,090,792 individuals. There were several key findings: (1) we found a high overall prevalence of RHD of varying from 5.2‰ to 26.1‰ depending on diagnostic criteria and procedure used. This prevalence was highest in studies which employed WHF criteria followed by those which used the WHO criteria (21.6‰ versus 11.3‰) and was also higher with echo > echo (21.2‰) procedure compared with auscultation > echo (15.6‰) procedure. (2) The prevalence RHD varied significantly with the level of income at country level, diagnostic criteria used and by region (i.e., higher in Africa than South East Asia); and (3) The lesions of over three-quarters of persons diagnosed with definite RHD either remained stable or progressed, while 11% of those diagnosed with borderline RHD progressed to definite RHD over 3.7-90 months of follow-up.
Globally, the prevalence of RHD was about three times greater for studies which used the echo > echo procedure compared with those which used the auscultation > echo diagnostic procedure. Echocardiography has been reported to be far more sensitive than cardiac auscultation in screening for RHD 43, 50, 56 . Marijon reported a failure of auscultation to detect more than 90% of RHD cases detected with echocardiography 38 . Auscultation is therefore an ineffective screening method for RHD, especially in endemic regions. This finding in accordance with endorsement of echocardiography as a screening tool for RHD in endemic areas by the WHO 104 . In this light, a number of studies have evaluated the sensitivity of a more conducive echocardiographic screening tool, the handheld echocardiography (HAND), which has demonstrated its superiority over auscultation 42, 76 www.nature.com/scientificreports www.nature.com/scientificreports/ is particular useful as it is associated with an acceptable sensitive and specificity for both borderline and definite RHD, and a sensitivity of greater than 90% of definite RHD when used by nurses 77 , and an excellent sensitivity and specificity when used by experienced physicians 81, 98 . In addition, it is less costly, and portable when compared with the standard echocardiography. This is critical in overcoming the limitation of large-scale echocardiographic screening in resource-limited settings.
The prevalence of RHD was over two times greater for studies employing the WHF diagnostic criteria than those using the WHO criteria. This discrepancy could be explained by: a difference in definition for case detection and diagnostic criteria for RHD 99, 104 ; the difficulties associated with large-scale screening; method of screening; and the period during which data was collected for the included studies. These findings could signify that the true prevalence of RHD is underrated or overrated by studies employing the WHO or WHF criteria, respectively. Indeed, the prevalence of definite RD was about twice greater for WHF studies than WHO studies. Furthermore, the prevalence of borderline RHD was over three times greater than that of probable RHD. The major reasons for moderate to high risk of bias in the prevalence of RHD from studies included in this systematic review and meta-analysis were: the use of auscultation in screening for RHD, non-randomized sampling, and failure to report on the study setting, appropriate numerator (number of cases of RHD) to compute the prevalence of RHD; the use of an acceptable case definition for RHD or study setting.
The relatively high prevalence of borderline RHD could be due to a high false-positive rate associated with the WHF criteria 76 . It is noteworthy that the clinical significance of borderline RHD in individuals with no prior history of ARF remains obscure. In fact, the WHF affirms that the recent criteria was "established to improve sensitivity at the expense of specificity, " and does not necessarily represent a diseased state 7 . Roberts et al. 76 in 2014 after screening a group of 3946 and 1053 children considered to be at high-and low-risk of RHD respectively, demonstrated that borderline RHD could be found in about 0.5% of the low-risk population. High positive rates are crucial because it may lead to unnecessary health expenditures on the part of individual and his/her family as they might be dealing with the wrong diagnosis of a chronic disease. Also, this further weighs on the healthcare system as there is the need to allocate adequate resources required for further evaluation of such potential cases, which is usually difficult in resource-poor settings. The high false-positive rate of the WHF diagnostic criteria cannot be completely disregarded due to its stronger association with populations at high-risk, compared with those at low-risk of RHD 76 .
There was no significant difference in the prevalence of RHD among school-based compared with community-based studies, and did not influence the variability of the prevalence of RHD globally. This is contrary to the hypothesis that school-based studies are likely to underrate the actual burden of RHD due to the association between school attendance and socioeconomic status; which in turn, is a principal risk factor for RHD 100 www.nature.com/scientificreports www.nature.com/scientificreports/ noted among children sampled in schools and the community 9 . However, with the inclusion of an unbalanced proportion of studies which used community-(64/82, 78%) compared with school-based interventions, this claim warrants further investigation. Engel et al. 30 , 2015 and Gemechu et al. 31 , 2017 estimated the prevalence of RHD in Ethiopian scholars and at population level respectively, two years apart. They noted a higher prevalence of RHD at population level (56.7 cases per 1000) than schools (31 cases per 1000).
The prevalence of clinically silent RHD was over twice greater than that of clinically manifest RHD. A higher ratio was noted by Rothenbühler et al. 9 . Asymptomatic persons with no history of acute rheumatic fever but presenting with echocardiographic signs of RHD are said to have a clinically silent RHD, which is a latent stage of RHD 101 34  8  18  3  114  11  2  30  157  22  61  60  52  24  54  546  16  429  7  36  15   207  180  7  11  32  55  61  57  1794  56  137  17  17  14  192  157  17  12  251  33  43  5  100  51  49  161  125  53  12  4  222  59   288  72  54  10  184  59  142  142  5  3  21  35  68  23  66  79  6  9  11  150  6  1  128  20  29  44 www.nature.com/scientificreports www.nature.com/scientificreports/ majority of the cases detected by active surveillance using echocardiography 42, 43, 50, 102 . The natural progression of latent RHD, which is still obscure, is associated with clinical and economic implications as to whether the affected individual should be placed on penicillin prophylaxis or not 105 . Although, it has been suggested that the progression of latent RHD can be halted by early institution of penicillin prophylaxis, this claim is yet to be confirmed by appropriate prospective studies 106, 107 . The natural progression of latent RHD has been evaluated by some prospective studies 40, 102, 105, 108 . However, appropriate comparison across cohorts is limited by small sample sizes, the use of non-standardized criteria for diagnosis of RHD, short duration of follow up, varying proportion of participants on penicillin prophylaxis and rates of adherence to penicillin prophylaxis. We noted that about 70% of children diagnosed with definite RHD either progressed or remained stable over time. It is crucial to report disease 34  18  288  11  184  2  142  5  3  157  21  23  66  79  61  6  12  251  9  60  52  24  6  54  546  1  429  29  44  7  7   8  114  72  180  54  10  7  11  59  32  30  55  61  57  1794  142  137  22  17  35  17  68  192  157  17  33  11  150  43  5  100  51  49  161  128  125  16  53  12  4  20  222  59  59  36  15   207  3  56  14 28 www.nature.com/scientificreports www.nature.com/scientificreports/ progression according to disease severity (mild, moderate and severe). Indeed, participants with moderate and/ or severe definite RHD have been reported to have a greater progression rate and poorer outcome than those with mild definite RHD 109, 110 . Secondary prophylaxis coupled with adherence enhancement as proposed by the WHF in 2012 is advised by some experts that individuals with moderate to severe forms of definite RHD 5 . Whether penicillin prophylaxis is able halt the progression of RHD still remains obscured and warrants further investigation 111 . In addition, about 11% of participants initially diagnosed with borderline RHD progressed to definite RHD. This finding suggests, to a minimum, that individuals with borderline disease need surveillance for disease progression as the process persists with time 112, 113 .
Despite the drastic drop in the prevalence of RHD in most high-income and some low-income countries such as Cuba, it still remains high in many developing countries 5, 114 . With the absence of an effective vaccine to prevent RHD, WHO experts endorsed a multilevel approach for the control and/or eradication of RHD which consists of: the improving the social economic and environmental conditions of at-risk populations, referred to as 'primordial prevention'; treating all patients with strep throat using penicillin -'primary prevention'; using antibiotic prophylaxis in persons with history of rheumatic fever or RHD prevent recurrence of an hence reduce progression of already established cardiac lesions, referred to as 'secondary prevention'; and treatment medically and/or surgically the complications of RHD, known as 'tertiary prevention' 7, 104 . However, the implementation of these recommendations faces several challenges 7 .
Though the meta-analytic techniques used in this study were robust, the findings herein should be interpreted with care taking into account the study limitations. Firstly, we noted substantial heterogeneity in the prevalence of RHD across countries and regions, however more than half of the heterogeneity was explained by the final multivariable model. Indeed, studies have shown significant differences in the prevalence of RHD, when the WHO diagnostic criteria of 2006 is compared with the WHF criteria of 2012 76 . Also, the WHF diagnostic criteria of 2012 have not been universally accepted 52, 53, 59 . Consequently, alternative guidelines have been adopted in many countries 115 . This might explain the heterogeneity of RHD observed across studies. Secondly, despite the superiority of echocardiography over auscultation in diagnosing RHD, there is still no gold standard for diagnosing RHD as echocardiography relies on criteria-specific sensitivity and specificity which needs to be improved. In fact, there are concerns that available echocardiographic criteria for diagnosing RHD might overestimate the actual burden of RHD 76 . Though, the age of participants included in this study spanned from 3 to 74 years, specific criteria for echo-based diagnosis of RHD and studies on the prevalence of RHD in adults, in whom we expect to be the vast majority in developing countries, are sparse. The current criteria for the diagnosis of subclinical RHD might not be appropriate in adults, as such criteria were developed and validated in children in which early diagnosis and intervention can positively impact the natural history of RHD. Thirdly, all WHO regions were not uniformly represented partly due to difficulties in retrieving the full-text of articles published in local journals. For example, there are regions represented by just a single study or two. The authors will advise the prevalence rates obtained for such regions not be taken into consideration when comparing the global prevalence of RHD according to the different WHO regions. More studies are needed in these regions reliable statistics concerning the prevalence of RHD in these regions. Finally, evidence from studies reporting on the evolution of clinically silent RHD are limited by small sample sizes, short duration of follow-up and non-standardized criteria for diagnosis and classification of RHD. This study reveals a high prevalence of RHD among WHO regions, with the highest rates recorded in Africa. The prevalence of RHD is highest with studies employing the WHF diagnostic criteria and those which use echocardiography for both screening and confirmation of RHD. Well-designed prospective studies with longer periods of follow-up, larger sample sizes to provide adequate data on the evolution of RHD and standardization of criteria to diagnose and classify RHD, preferably in the context of randomized trials of the effectiveness of antibiotic prophylaxis, are warranted to inform the management of asymptomatic RHD detected on screening echocardiography.
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